⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNTI News
Senti Biosciences, Inc. Common Stock
Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
globenewswire.com
SNTI
Senti Biosciences Announces New Employment Inducement Grants
globenewswire.com
SNTI
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile
globenewswire.com
SNTI
Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia
globenewswire.com
SNTI
Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET
globenewswire.com
SNTI
Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December
globenewswire.com
SNTI
Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025
globenewswire.com
SNTI
Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference
globenewswire.com
SNTI
Senti Bio to Present at BioJapan
globenewswire.com
SNTI